Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Antiandrogens  COVID-19 treatment studies for Antiandrogens  C19 studies: Antiandrogens  Antiandrogens   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -25% Improvement Relative Risk c19early.org/aa Gedeborg et al. Antiandrogens for COVID-19 Prophylaxis Is prophylaxis with antiandrogens beneficial for COVID-19? Retrospective 24,174 patients in Sweden Higher mortality with antiandrogens (not stat. sig., p=0.11) Gedeborg et al., Scandinavian J. Urology, doi:10.1080/21681805.2021.2019304 Favors antiandrogen Favors control
Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer
Gedeborg et al., Scandinavian Journal of Urology, doi:10.1080/21681805.2021.2019304
Gedeborg et al., Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate.., Scandinavian Journal of Urology, doi:10.1080/21681805.2021.2019304
Dec 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Case control study with 474 patients that died of COVID-19 in Sweden, showing higher risk with ADT, without statistical significance.
risk of death, 25.0% higher, OR 1.25, p = 0.11, treatment 271 of 474 (57.2%) cases, 5,181 of 23,700 (21.9%) controls, case control OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gedeborg et al., 23 Dec 2021, retrospective, Sweden, peer-reviewed, 6 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAntiandrogensAll
Abstract: Scandinavian Journal of Urology ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/isju20 Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer Rolf Gedeborg, Lars Lindhagen, Stacy Loeb, Johan Styrke, Hans Garmo & Pär Stattin To cite this article: Rolf Gedeborg, Lars Lindhagen, Stacy Loeb, Johan Styrke, Hans Garmo & Pär Stattin (2021): Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer, Scandinavian Journal of Urology, DOI: 10.1080/21681805.2021.2019304 To link to this article: https://doi.org/10.1080/21681805.2021.2019304 © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group View supplementary material Published online: 23 Dec 2021. Submit your article to this journal Article views: 949 View related articles View Crossmark data Citing articles: 1 View citing articles Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=isju20 SCANDINAVIAN JOURNAL OF UROLOGY https://doi.org/10.1080/21681805.2021.2019304 Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer Rolf Gedeborga , Lars Lindhagenb, Stacy Loebc, Johan Styrked, Hans Garmoa,e and P€ar Stattina a Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; bUppsala Clinical Research Center (UCR), Uppsala, Sweden; Department of Urology and Population Health, New York University and Manhattan Veterans Affairs Medical Center, New York, NY, USA; d Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden; eTranslational Oncology and Urology Research (TOUR), King’s College London, Guy’s Hospital, London, UK c ABSTRACT ARTICLE HISTORY Background: Androgens facilitate entrance of the severe acute respiratory syndrome coronavirus 2 into respiratory epithelial cells, and male sex is associated with a higher risk of death from corona virus disease (COVID-19). Androgen deprivation therapy (ADT) could possibly improve COVID19 outcomes. Methods: In a case–control study nested in the Prostate Cancer data Base Sweden (PCBaSe) RAPID 2019, we evaluated the association between ADT and COVID-19 as registered cause of death in men with prostate cancer. Each case was matched to 50 controls by region. We used conditional logistic regression to adjust for confounders and also evaluated potential impact of residual confounding. Results: We identified 474 men who died from COVID-19 in March–December 2020. In crude analyses, ADT exposure was associated with an increased risk of COVID-19 death (odds ratio [OR] 5.05, 95% CI: 4.18–6.10); however, the OR was substantially attenuated after adjustment for age, comorbidity, prostate cancer characteristics at diagnosis, recent healthcare use, and indicators of advanced cancer (adjusted OR 1.25, 95% CI: 0.95–1.65). If adjustment has accounted for at least 85% of confounding, then the true effect could be no more than a 5% reduction of the odds for COVID-19 death. Conclusions: The increased mortality from COVID-19 in men with prostate cancer treated with ADT was mainly related to high age, comorbidity, and more advanced prostate cancer. There was no evidence to support the hypothesis that ADT is associated with improved COVID-19 outcomes. Received 5 October 2021 Accepted 30 November..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit